BSGM - BioSig Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.4600
-0.0100 (-0.22%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.4700
Open4.5000
Bid4.10 x 1000
Ask4.56 x 1200
Day's Range4.3500 - 4.5800
52 Week Range1.2850 - 7.8750
Volume38,546
Avg. Volume51,545
Market Cap74.321M
Beta (3Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-1.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.75
Trade prices are not sourced from all markets
  • Moving Average Crossover Alert: Biosig Technologies, Inc.
    Zackslast month

    Moving Average Crossover Alert: Biosig Technologies, Inc.

    Biosig Technologies could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • GlobeNewswire2 months ago

    BioSig Technologies To Commence First–in-Human Studies at Mayo Clinic

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Mayo Clinic to conduct First-in-Human studies using the PURE EP™ System. Mayo Clinic has conducted twelve pre-clinical studies to date using the PURE EP™ System, results of which have been published in a number of journals, including The Journal of Innovations in Cardiac Rhythm Management.

  • GlobeNewswire2 months ago

    Medical Leaders Join BioSig Clinical Advisory Board

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company formed a Clinical Advisory Board to complement existing scientific relationships with the nationwide key opinion leaders built during the R&D phase of product development. The goal of the newly formed Board is to advise the Company on a range of aspects related to commercialization of BioSig’s novel signal acquisition and processing technology, PURE EP(tm) System.

  • Could The BioSig Technologies Inc (NASDAQ:BSGM) Ownership Structure Tell Us Something Useful?
    Simply Wall St.2 months ago

    Could The BioSig Technologies Inc (NASDAQ:BSGM) Ownership Structure Tell Us Something Useful?

    Every investor in BioSig Technologies Inc (NASDAQ:BSGM) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • GlobeNewswire2 months ago

    BioSig Technologies Signs Agreement with Texas Cardiac Arrhythmia Institute for First–in-Human Studies

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in Austin, Texas to conduct First-in-Human studies using the PURE EP™ System.

  • GlobeNewswire2 months ago

    BioSig Technologies Announces New Research Program with Mayo Clinic

    The new program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. The program will consist of a number of two-to three-year projects, which will focus on development of additional advanced features of PURE EP(tm) System within the field of electrophysiology and potential clinical applications of BioSig’s technology in a new, previously unexplored, field.

  • GlobeNewswire2 months ago

    BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018

    Santa Monica, CA, Nov. 12, 2018 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal.

  • GlobeNewswire3 months ago

    BioSig Technologies Opens Business Office in Norwalk, CT

    The new office will complement the Company’s headquarters in Los Angeles, CA and administration and finance office in Austin, TX. Norwalk office becomes the Company’s first location on the East Coast and will serve as the commercialization, sales support, investor relations and business development location.

  • GlobeNewswire3 months ago

    BioSig Technologies to Present at the 4th Annual Dawson James Small Cap Growth Conference

    BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it will be presenting at the 4th annual Dawson James Small Cap Growth Conference. Mr. Kenneth Londoner, Founder, Chairman & CEO of BioSig Technologies, Inc., will do a presentation on October 30th on the Company’s progress, including recent uplist to Nasdaq, the FDA 510(k) clearance for the Company’s proprietary PURE EP(TM) System, as well as other business highlights.

  • Zacks Small Cap Research3 months ago

    BSGM: PURE EP Launch Timing Aligns Well With Attractive Market Fundamentals

    BioSig Technologies Inc. (BSGM) is a medical device company engaged in the development and commercialization of a proprietary signal processing platform designed to significantly improve real-time information and clinical decision-making in the ~$4B - $5B electrophysiology (EP) market. Following receipt of FDA 510(k) clearance in early August and subsequently uplisting their shares to Nasdaq, BioSig is readying for launch of the PURE EP System while simultaneously ramping up investor outreach efforts. In late August they hired Amy Scott, a seasoned medical device professional with more than two decades’ experience in the electrophysiology space, to lead the launch.

  • Zacks Small Cap Research4 months ago

    BSGM: PURE EP Poised For Strong U.S. Launch

    Following receipt of FDA 510(k) clearance in early August and uplisting their shares to Nasdaq, BioSig Technologies Inc. (BSGM) is readying for launch of their flagship product, the PURE EP System, and simultaneously ramping up investor outreach efforts. BioSig is a medical device company engaged in the development and commercialization of a proprietary signal processing platform designed to significantly improve real-time information and clinical decision-making in the ~$4B - $5B electrophysiology (EP) market. When drug therapy fails to control certain complex heart conditions such as atrial fibrillation and ventricular tachycardia, cardiologists often turn to catheter ablation.